In the dazzling narrative of cryptocurrencies, Injective proves itself not to be a project that 'only tells stories' with a series of tangible actions. The native EVM is about to launch, allowing developers to deploy high-performance, cross-chain DeFi protocols in an Ethereum-compatible environment. Over 40 dApps and infrastructure partners are queued to enter, and the entire ecosystem's landscape is rapidly expanding, laying a solid foundation for on-chain financial innovation.

Actions on the capital side also provide ample room for imagination. NYSE-listed company Pineapple Financial is putting up $100 million, planning to continuously buy INJ in the secondary market; meanwhile, Injective's ETF will also land in the U.S. market, allowing both institutions and retail investors to participate through compliant channels. This not only enhances the market depth of INJ but also reflects traditional finance's bet on its long-term value.

On the narrative level, RWA is the most recognizable piece of the Injective puzzle. Assets such as stocks, gold, foreign exchange, and digitized government bonds have already been moved on-chain, and even stocks like Nvidia can be traded directly on-chain. Investors can access real-world assets in a DeFi environment while enjoying transparent, efficient, and composable financial tools.

While many public chains are still stuck on 'user acquisition' and 'hot topics,' Injective is quietly positioning itself as part of the global financial infrastructure. Its true value is not just the INJ token but its ability to reconstruct future financial order and capital flow.